Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076050 · ClinicalTrials.gov registry record · Phase 3
Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
A Phase 3 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 3
- Development phase
- 248
- Enrollment target
NCT00076050: Completed Phase 3 study, sponsored by University of Miami.
NCT00076050 is a Phase 3 study that has completed, run by University of Miami. The registered enrollment target is 248 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00076050, a Phase 3 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 248 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women who have recently gone through menopause. Study hypothesis: Tablets of high-dose, purified soy phytoestrogens spare the normally occurring spinal bone loss and improve biological and other emotional changes of menopause.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Soy isoflavones
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00076050 record still lists
NCT00076050 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00076050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00076050 about?
NCT00076050 is a clinical study titled "Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms". The purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women who have recently gone through menopause. Study hypothesis: Tablets of high-dose, purified soy phytoestrogens spar...
What is the current status of trial NCT00076050?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 248 participants. The study started on 2003-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00076050?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Soy isoflavones (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00076050?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00076050's enrollment target sits among peer trials
248 1266th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia